Christopher Anzalone - May 3, 2023 Form 4 Insider Report for ARROWHEAD PHARMACEUTICALS, INC. (ARWR)

Role
Chief Executive Officer, Director
Signature
/s/Christopher Anzalone
Stock symbol
ARWR
Transactions as of
May 3, 2023
Transactions value $
-$3,914,768
Form type
4
Date filed
5/5/2023, 07:04 PM
Previous filing
Dec 20, 2022
Next filing
Sep 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ARWR Common Stock Options Exercise $110K +54.9K +1.46% $2.01* 3.82M May 3, 2023 Direct F1
transaction ARWR Common Stock Sale -$2.15M -54.9K -1.44% $39.14 3.76M May 3, 2023 Direct F2
transaction ARWR Common Stock Options Exercise $101K +50K +1.33% $2.01* 3.81M May 4, 2023 Direct F1
transaction ARWR Common Stock Sale -$936K -24K -0.63% $38.97 3.79M May 4, 2023 Direct F3
transaction ARWR Common Stock Sale -$1.04M -26K -0.69% $40.02 3.76M May 4, 2023 Direct F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ARWR Stock Option (right to buy) Options Exercise $0 -54.9K -9.6% $0.00 517K May 3, 2023 Common Stock 54.9K $2.01 Direct F5, F6
transaction ARWR Stock Option (right to buy) Options Exercise $0 -50K -9.67% $0.00 467K May 4, 2023 Common Stock 50K $2.01 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Acquired through exercise of options expiring 5/6/23. See Table II.
F2 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.84 to $39.56, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F3 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.47 to $39.47, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F4 The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $39.48 to $40.46, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4.
F5 Represents first vesting date. Option vested over four years from date of grant.
F6 Represents total stock options beneficially owned at various strike prices.